United Therapeutics Stock EBITDA

UTHR Stock

USD 370.49 7.64 2.02%

United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.

		Last Reported	Projected for Next Year
	EBITDA	1.4 B	1.5 B

As of 12/01/2024, EBITDA is likely to grow to about 1.5 B.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

United Therapeutics Company EBITDA Analysis

United Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current United Therapeutics EBITDA

1.39 B

Most of United Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

United EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as EBITDA. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Good Will	Short Term Investments	Short Term Debt	Intangible Assets	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.14	0.97	-0.22	0.74	0.89	0.99	0.92	0.95	0.83	0.48	0.47	0.57	-0.69	0.96	0.4	0.98	0.82	0.82	0.93	0.91	0.91	0.89	-0.86
Total Stockholder Equity	1.0		-0.19	0.98	-0.22	0.74	0.85	0.99	0.91	0.95	0.81	0.47	0.43	0.52	-0.68	0.95	0.37	0.99	0.8	0.81	0.92	0.91	0.91	0.89	-0.84
Net Debt	-0.14	-0.19		-0.26	0.12	-0.58	0.12	-0.23	-0.01	0.06	0.13	0.03	-0.28	0.45	0.41	-0.17	0.05	-0.15	0.03	-0.34	0.11	-0.03	0.01	0.01	-0.2
Retained Earnings	0.97	0.98	-0.26		-0.28	0.78	0.83	0.98	0.92	0.89	0.75	0.54	0.46	0.55	-0.8	0.94	0.22	0.97	0.81	0.87	0.87	0.91	0.88	0.86	-0.83
Accounts Payable	-0.22	-0.22	0.12	-0.28		-0.21	-0.2	-0.26	-0.13	-0.2	0.02	0.05	0.06	-0.11	0.28	-0.15	0.14	-0.27	-0.23	-0.36	-0.22	-0.25	-0.28	-0.26	0.32
Net Receivables	0.74	0.74	-0.58	0.78	-0.21		0.63	0.77	0.59	0.54	0.56	0.26	0.65	0.18	-0.76	0.78	0.3	0.69	0.48	0.74	0.55	0.61	0.51	0.5	-0.41
Total Liab	0.89	0.85	0.12	0.83	-0.2	0.63		0.85	0.84	0.83	0.82	0.46	0.6	0.74	-0.68	0.91	0.49	0.82	0.83	0.75	0.84	0.79	0.8	0.77	-0.88
Total Current Assets	0.99	0.99	-0.23	0.98	-0.26	0.77	0.85		0.89	0.94	0.78	0.45	0.47	0.53	-0.73	0.95	0.36	0.98	0.8	0.84	0.88	0.89	0.9	0.9	-0.83
Good Will	0.92	0.91	-0.01	0.92	-0.13	0.59	0.84	0.89		0.88	0.76	0.73	0.47	0.64	-0.74	0.93	0.22	0.89	0.78	0.79	0.84	0.85	0.83	0.8	-0.83
Short Term Investments	0.95	0.95	0.06	0.89	-0.2	0.54	0.83	0.94	0.88		0.81	0.42	0.31	0.6	-0.52	0.88	0.4	0.96	0.78	0.7	0.93	0.87	0.94	0.95	-0.86
Short Term Debt	0.83	0.81	0.13	0.75	0.02	0.56	0.82	0.78	0.76	0.81		0.35	0.47	0.61	-0.46	0.81	0.46	0.79	0.65	0.53	0.85	0.86	0.75	0.73	-0.72
Intangible Assets	0.48	0.47	0.03	0.54	0.05	0.26	0.46	0.45	0.73	0.42	0.35		0.32	0.38	-0.59	0.55	-0.13	0.43	0.45	0.51	0.36	0.48	0.37	0.31	-0.48
Common Stock	0.47	0.43	-0.28	0.46	0.06	0.65	0.6	0.47	0.47	0.31	0.47	0.32		0.35	-0.65	0.64	0.47	0.35	0.48	0.65	0.26	0.3	0.36	0.33	-0.29
Long Term Debt	0.57	0.52	0.45	0.55	-0.11	0.18	0.74	0.53	0.64	0.6	0.61	0.38	0.35		-0.54	0.55	0.14	0.54	0.78	0.55	0.62	0.64	0.63	0.65	-0.78
Treasury Stock	-0.69	-0.68	0.41	-0.8	0.28	-0.76	-0.68	-0.73	-0.74	-0.52	-0.46	-0.59	-0.65	-0.54		-0.75	0.04	-0.65	-0.69	-0.89	-0.48	-0.66	-0.55	-0.54	0.59
Property Plant Equipment	0.96	0.95	-0.17	0.94	-0.15	0.78	0.91	0.95	0.93	0.88	0.81	0.55	0.64	0.55	-0.75		0.46	0.91	0.76	0.82	0.84	0.82	0.82	0.79	-0.79
Current Deferred Revenue	0.4	0.37	0.05	0.22	0.14	0.3	0.49	0.36	0.22	0.4	0.46	-0.13	0.47	0.14	0.04	0.46		0.31	0.24	0.16	0.4	0.15	0.31	0.3	-0.25
Net Tangible Assets	0.98	0.99	-0.15	0.97	-0.27	0.69	0.82	0.98	0.89	0.96	0.79	0.43	0.35	0.54	-0.65	0.91	0.31		0.8	0.79	0.94	0.92	0.93	0.92	-0.85
Long Term Debt Total	0.82	0.8	0.03	0.81	-0.23	0.48	0.83	0.8	0.78	0.78	0.65	0.45	0.48	0.78	-0.69	0.76	0.24	0.8		0.87	0.78	0.81	0.9	0.85	-0.91
Capital Surpluse	0.82	0.81	-0.34	0.87	-0.36	0.74	0.75	0.84	0.79	0.7	0.53	0.51	0.65	0.55	-0.89	0.82	0.16	0.79	0.87		0.65	0.74	0.8	0.76	-0.72
Long Term Investments	0.93	0.92	0.11	0.87	-0.22	0.55	0.84	0.88	0.84	0.93	0.85	0.36	0.26	0.62	-0.48	0.84	0.4	0.94	0.78	0.65		0.9	0.91	0.86	-0.88
Short Long Term Debt	0.91	0.91	-0.03	0.91	-0.25	0.61	0.79	0.89	0.85	0.87	0.86	0.48	0.3	0.64	-0.66	0.82	0.15	0.92	0.81	0.74	0.9		0.87	0.84	-0.85
Net Invested Capital	0.91	0.91	0.01	0.88	-0.28	0.51	0.8	0.9	0.83	0.94	0.75	0.37	0.36	0.63	-0.55	0.82	0.31	0.93	0.9	0.8	0.91	0.87		0.97	-0.89
Net Working Capital	0.89	0.89	0.01	0.86	-0.26	0.5	0.77	0.9	0.8	0.95	0.73	0.31	0.33	0.65	-0.54	0.79	0.3	0.92	0.85	0.76	0.86	0.84	0.97		-0.84
Capital Stock	-0.86	-0.84	-0.2	-0.83	0.32	-0.41	-0.88	-0.83	-0.83	-0.86	-0.72	-0.48	-0.29	-0.78	0.59	-0.79	-0.25	-0.85	-0.91	-0.72	-0.88	-0.85	-0.89	-0.84

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict United Therapeutics

Ebitda Over Time

United Ebitda

Ebitda

1.46 Billion

At this time, United Therapeutics' EBITDA is relatively stable compared to the past year.

According to the company disclosure, United Therapeutics reported earnings before interest,tax, depreciation and amortization of 1.39 B. This is 58.05% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 64.43% higher than that of the company.

United EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.

United Therapeutics is currently under evaluation in ebitda category among its peers.

United Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

United Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in United Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of United Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing United Therapeutics' value.

		Shares
Dimensional Fund Advisors, Inc.	2024-09-30	621 K
Fuller & Thaler Asset Management Inc	2024-09-30	568.4 K
Pacer Advisors, Inc.	2024-06-30	561.8 K
Alliancebernstein L.p.	2024-06-30	539.6 K
Amundi	2024-06-30	473 K
Arrowstreet Capital Limited Partnership	2024-06-30	438.7 K
Bank Of New York Mellon Corp	2024-06-30	434.8 K
Nuveen Asset Management, Llc	2024-06-30	434.5 K
Genworth Financial Wealth Mgmt Inc	2024-09-30	420 K
Blackrock Inc	2024-06-30	5.5 M
Vanguard Group Inc	2024-09-30	4.4 M

United Fundamentals

	Return On Equity	0.19
	Return On Asset	0.12
	Profit Margin	0.40 %
	Operating Margin	0.55 %
	Current Valuation	13.61 B
	Shares Outstanding	44.64 M
	Shares Owned By Insiders	1.84 %
	Shares Owned By Institutions	98.16 %
	Number Of Shares Shorted	2.21 M
	Price To Earning	23.49 X
	Price To Book	2.71 X
	Price To Sales	6.12 X
	Revenue	2.33 B
	Gross Profit	1.78 B
	EBITDA	1.39 B
	Net Income	984.8 M
	Cash And Equivalents	2.26 B
	Cash Per Share	49.55 X
	Total Debt	700 M
	Debt To Equity	0.18 %
	Current Ratio	8.10 X
	Book Value Per Share	136.74 X
	Cash Flow From Operations	978 M
	Short Ratio	5.72 X
	Earnings Per Share	22.75 X
	Price To Earnings To Growth	1.60 X
	Target Price	382.22
	Number Of Employees	1.17 K
	Beta	0.56
	Market Capitalization	16.88 B
	Total Asset	7.17 B
	Retained Earnings	6.03 B
	Working Capital	2.75 B
	Current Asset	1.28 B
	Current Liabilities	440.82 M
	Net Asset	7.17 B

About United Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.64	EWTX	Edgewise Therapeutics	Pair Corr
0.65	BHC	Bausch Health Companies	Pair Corr

Moving against United Stock

0.7	HLN	Haleon plc	Pair Corr
0.67	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.66	ZTS	Zoetis Inc	Pair Corr
0.65	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.56	LLY	Eli Lilly	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC